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Abst rac t
Some observations suggest that in some patients with multi-
ple sclerosis demyelination may affect the central and periphe -
ral nervous systems at the same time. The influence of immu -
nomodulatory therapy on peripheral nervous system damage
in these patients is still unknown. We present a 43-year-old
male patient with multiple sclerosis diagnosed at the age of
35 in whom flaccid tetraparesis with dysaesthesia preceded
by paraesthesias of four limbs occurred one year after start-
ing glatiramer acetate. The course of peripheral nervous sys-
tem disease and results of cerebrospinal fluid examination and
electromyography confirmed Guillain-Barré syndrome. Inter-
fering in the immunological system, glatiramer acetate may
have contributed to the development of the symptoms of Guil-
lain-Barré syndrome in our patient. The final improvement
of the patient’s condition may have resulted not only from the
applied treatment and the natural course of the disease, but
may have also been associated with the discontinuation of
glatiramer acetate.
Key words: Guillain-Barré syndrome, multiple sclerosis, gla-
tiramer acetate.
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CASE REPORT/OPIS PRZYPADKU
St reszczenie
W ostatnich latach zaobserwowano, ¿e u niektórych chorych
na stwardnienie rozsiane demielinizacja dotyczy tak¿e obwo-
dowego uk³adu nerwowego. Wp³yw leczenia immunomodu-
luj¹cego na ten typ uszkodzenia pozostaje niejasny. W pracy
przedstawiono przypadek 43-letniego mê¿czyzny, u którego
stwardnienie rozsiane rozpoznano w 35. roku ¿ycia i u któ-
rego rok po rozpoczêciu leczenia octanem glatirameru wy st¹ -
pi³a nagle wiotka tetrapareza z zaburzeniami czucia. Badanie
p³ynu mózgowo-rdzeniowego oraz badanie elektromiogra-
ficzne potwierdzi³y rozpoznanie zespo³u Guillaina-Barrégo.
Leczenie octanem glatirameru mog³o siê przyczyniæ do wy st¹-
pienia tego zespo³u u opisywanego pacjenta. Uzys kana popra-
wa stanu chorego mog³a byæ wynikiem stosowanego leczenia
i naturalnego przebiegu choroby, nie mo¿na te¿ pomin¹æ zna-
czenia odstawienia glatirameru.
S³owa kluczowe: zespó³ Guillaina-Barrégo, stwardnienie roz-
siane, octan glatirameru.
Introduction
As early as in the second half of the 20th century, it
was supposed that demyelination may affect the central
and peripheral nervous systems at the same time. The pro-
portion of multiple sclerosis (MS) patients in whom
abnormalities in the electrophysiological examination of
peripheral nerves were found varies considerably, from
5% to 74.2% [1-6]. In almost all the reports of changes
in the examined peripheral nerves in MS patients, the da -
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mage to those nerves was mostly demyelinating, and it
was asymptomatic in most cases.
In the literature there are few cases of Guillain-Barré
syndrome (GBS) occurring in patients with clinically
definite MS [7]. In 2008, Sharma et al. [8] described
five cases of chronic inflammatory demyelinating poly -
neuropathy (CIDP) which developed in MS patients.
None of those patients was treated with interferon beta,
so the possibility of inducing polyneuropathy by this
drug was excluded. Ekstein et al. [2] des cribed six cas-
es of neuropathy caused by interferon beta in MS pa -
tients. Neuropathy receded in five patients after the dis-
continuation of this treatment, and the re-introduction
of this drug caused the recurrence of neuropathy in two
patients [2]. In the MS patients described by Pirko 
et al. [5], CIDP developed after 4 months, 1 year and
4 years, respectively from the beginning of treatment
with interferon beta. 
Case report
We report the case of a 43-year-old man with relaps-
ing-remitting form of MS who developed Guillain-
Barré syndrome after one year of treatment with glati-
ramer acetate. The patient was diagnosed with MS at
the age of 35. The disease course was relapsing-remitt -
ing with approximately one exacerbation each other year.
The patient met revised McDonald’s [9] criteria with
both clinical presentation and additional examinations;
magnetic resonance imaging of the brain showed mul-
tiple and mainly periventricular demyelinating lesions;
visual evoked potentials were abnormal, cell count and
protein level in cerebrospinal fluid were within the nor-
mal range. The patient was ambulatory with Expanded
Disability Status Scale score of 2.0. Glatiramer acetate
treatment was started in April 2007. In April 2008, the
patient developed flaccid tetraparesis with lack of ten-
don reflexes (III/IV on Lovett scale) and polyneuropa -
thic dysaesthesias preceded by paraesthesias of calf and
feet.
Over the following few days, symptoms worsened to
bilateral facial paralysis and flaccid paralysis of the low-
er limbs. These symptoms coincided with a respiratory
tract infection (right-sided pneumonia) confirmed by
X-ray examination. The examination of the cerebrospinal
fluid showed an increase in protein level (54 mg/dL)
with cell count within the normal range. Electroneuro-
graphic examination showed signs of axonal demy-
e li nating sensory motor neuropathy. Tests for ANA, 
dsDNA and anti-Borrelia antibodies were negative.
Neuroimaging examination of the head and the cervi-
cal spine did not show new active demyelinating lesions.
The patient was diagnosed with Guillain-Barré syn-
drome. Treatment with glatiramer acetate was with-
drawn. The patient received antibiotics and immu -
noglobulins at the dose of 0.4 mg/kg/day for five
consecutive days. A significant improvement in the func-
tion of the limbs as well as a slight improvement of 
the electroneurographic parameters were achieved. Facial
paresis persisted. The continued, several-month long
rehabilitation of the patient brought further normalisa-
tion of the neurological condition and the electroneuro-
graphic findings.
Discussion
Glatiramer acetate consists of acetate salts of oligo -
peptides composed of four naturally occurring amino
acids. Glatiramer acetate influences immune cells in an
antigen-specific way. Administered chronically, it acts as
an antigen-based therapeutic vaccine. Glatiramer acetate
oligopeptides administered subcutaneously interact with
antigen presenting cells and blood lymphocytes locally
at the site of injection. The systemic immune response
is mediated by circulating activated glatiramer acetate-
reactive T cells. Glatiramer acetate-specific Th2 cells
cross the blood-brain barrier and, accumulated in the
CNS, release anti-inflammatory cytokines inhibiting
nearby immune cells (bystander suppression mecha-
nism) [10-13]. Additionally, these Th2 cells secrete neu-
rotrophic substances (e.g. brain-derived neurotrophic
factor) which might mediate suggested glatiramer acetate
neuroprotective activity. All patients treated with glati-
ramer acetate develop specific antibodies against the
drug which reach peak levels after 3-6 months of ther-
apy and then stabilize at low levels. Glatiramer acetate
oligopeptides also stimulate peripheral blood lympho-
cytes; the initial Th1 pro-inflammatory response with
repeated administration of glatiramer acetate switches
to the Th2 anti-inflammatory type [14].
We have not found a description of the occurrence
of Guillain-Barré syndrome in an MS patient treated
with glatiramer acetate. There was however a success-
ful trial to treat experimental autoimmune neuritis
(which is an experimental model of Guillain-Barré syn-
drome in mice) with glatiramer acetate [15]. The mech-
anism in which glatiramer acetate might have con-
tributed to the development of Guillain-Barré syndrome
in our patient is uncertain. Cross-reaction of peripher-
al nerve myelin antigens with glatiramer acetate-speci -
Neurologia i Neurochirurgia Polska 2012; 46, 2 191
Guillain-Barré syndrome in MS patient treated with glatiramer acetate
fic antibodies after one year of therapy is rather ques-
tionable. The patient suffered from pneumonia, which
often precedes Guillain-Barré syndrome. It cannot be
excluded that modulation of the immune system with
glatiramer acetate treatment eased immunopathological
processes which led to Guillain-Barré syndrome devel-
opment. The improvement of the patient’s condition
may have resulted not only from the applied treatment
and the natural course of the disease, but may have also
been associated with the discontinuation of glatiramer
acetate. One thing is certain in this case: glatiramer ace -
tate treatment did not prevent Guillain-Barré syndrome
development in our patient.
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